SFC
AXSM icon

Strategic Financial Concepts’s Axsome Therapeutics AXSM Stock Holding History

Strategic Financial Concepts’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-26,010
Closed -$306 – 275
2024
Q2 		$306 Buy
+26,010
New +$1.93M ﹤0.01% 678

Other funds holding AXSM

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Strategic Financial Concepts's AXSM Position: Q3 2024 in Review

Strategic Financial Concepts sold out of Axsome Therapeutics (AXSM) in Q3 2024, closing a stake of 26,010 shares — an estimated $306 sold.

Strategic Financial Concepts first reported a position in AXSM in Q2 2024 and held it in 1 quarter. The position peaked at $306 in Q2 2024. 278 funds tracked by Wall St. Rank hold AXSM as of Q3 2024.

  • Strategic Financial Concepts reported no remaining Axsome Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Strategic Financial Concepts sold 26,010 Axsome Therapeutics shares in Q3 2024, an estimated $306.
  • Strategic Financial Concepts first reported a position in Axsome Therapeutics in Q2 2024 and held it in 1 quarter.
  • Strategic Financial Concepts's Axsome Therapeutics position peaked at $306 in Q2 2024.
  • 278 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q3 2024.

Based on Strategic Financial Concepts's 13F filing for Q3 2024, filed 12 Nov 2024.